Mutual fund giant T Rowe Price Group is urging Allergan Inc to allow shareholders to vote on any major acquisitions as the Botox maker scrambles to fend off a hostile bid by Valeant Pharmaceuticals International Inc T Rowe Allergans secondlargest shareholder with a roughly  stake said in a statement it is concerned Allergan could strike a deal that would hamper a pending shareholder vote that is a necessary step in Valeants  billion bid with activist investor William Ackman to take over Allergan 